Rhodiola Rosea
Clinically-studied adaptogen that modulates the HPA axis - blunting excess cortisol output without sedation. EMA-assessed for mental fatigue and stress. Standardisation ratio is critical: rosavins and salidroside must both be verified.
Mechanism
Rhodiola rosea is a well-characterised adaptogen - a compound that increases non-specific resistance to stress without impairing normal function. Its primary mechanism involves modulation of the HPA (hypothalamic-pituitary-adrenal) axis: blunting the cortisol stress response while maintaining alertness and cognitive function.
The European Medicines Agency (EMA) has assessed Rhodiola for mental fatigue and stress, giving it a positive opinion based on clinical evidence. The standardisation ratio is critical for efficacy - the two active compound classes (rosavins and salidroside) must both be verified by HPLC. Products with only rosavin standardisation are incomplete.
Key Benefits
- Traditional Scandinavian and Siberian adaptogen, used for centuries
- Standardised to ≥3% rosavins and ≥1% salidroside. The most-studied markers
- Supports cognitive performance under stressful conditions
- EMA-assessed for traditional use in stress and mental fatigue
- Effects accumulate with consistent daily use
The Research
Peer-reviewed human trials supporting this ingredient at this dose.
Rhodiola Rosea
350mg≥3.0% rosavins / ≥1.0% salidroside - HPLC verified at source
Morning or pre-stressful activity. Avoid taking in the evening - can be mildly stimulating. Consistent daily use produces strongest HPA axis modulation effects.